Arrowstreet Capital
KNSA icon

Arrowstreet Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Arrowstreet Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.2M Buy
957,514
+64,848
+7% +$3.36M 0.03% 491
2026
Q1 		$43M Sell
892,666
-175,550
-16% -$7.78M 0.02% 536
2025
Q4 		$44.1M Sell
1,068,216
-47
-0% -$1.89K 0.03% 519
2025
Q3 		$41.5M Buy
1,068,263
+332,846
+45% +$10.8M 0.03% 514
2025
Q2 		$20.3M Buy
+735,417
New +$18.7M 0.01% 685
2025
Q1 		– Sell
-22,453
Closed -$444K – 1913
2024
Q4 		$444K Sell
22,453
-139,190
-86% -$3.18M ﹤0.01% 1578
2024
Q3 		$4.04M Buy
161,643
+21,582
+15% +$526K ﹤0.01% 1028
2024
Q2 		$2.62M Sell
140,061
-45,752
-25% -$857K ﹤0.01% 1006
2024
Q1 		$3.67M Buy
185,813
+109,061
+142% +$2.13M ﹤0.01% 978
2023
Q4 		$1.35M Buy
76,752
+4,037
+6% +$66.4K ﹤0.01% 1046
2023
Q3 		$1.26M Buy
+72,715
New +$1.23M ﹤0.01% 940

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arrowstreet Capital's KNSA Position: Q2 2026 in Review

Arrowstreet Capital increased its Kiniksa Pharmaceuticals (KNSA) stake by 7.3% in Q2 2026, buying an estimated $3.36M and bringing the position to 957,514 shares worth $61.2M. The position accounts for 0.03% of the portfolio, ranked #491.

Arrowstreet Capital first reported a position in KNSA in Q3 2023 and has held it in 11 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Arrowstreet Capital held 957,514 shares of Kiniksa Pharmaceuticals worth $61.2M as of Q2 2026.
  • Arrowstreet Capital bought 64,848 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.36M.
  • Kiniksa Pharmaceuticals made up 0.03% of Arrowstreet Capital's portfolio in Q2 2026, its #491 holding.
  • Arrowstreet Capital first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.